Regeneron Ending Eylea, Nesvacumab Combo Program

December 1, 2017: By Jon Swedien

Regeneron is ending the Eylea and nesvacumab combination program it had been developing with Bayer AG, the Tarrytown, New York, company announced Nov. 27.

Results from two Phase II studies that added the angiopoietin2 (Ang2) antibody nesvacumab to an Eylea (aflibercept) injection did not provide sufficient differentiation from Eylea monotherapy to warrant Phase III development, Regeneron said.

The RUBY study evaluated patients with diabetic macular edema (DME), and the ONYX study evaluated patients with wet age-related macular degeneration (wet AMD).

The randomized, double-masked studies evaluated two doses of nesvacumab in combination with aflibercept, both administered as a single co-formulated intravitreal injection, as well as aflibercept monotherapy. The primary endpoint for both trials was change in best-corrected visual acuity between week 12 and 36 as measured by the Early Treatment Diabetic Retinopathy Study letter score.

Eylea results were consistent with findings in previous clinical studies, and there were no new safety signals in these studies, Regeneron said.

The combination of aflibercept and nesvacumab was being jointly developed by Regeneron and Bayer AG under a global collaboration agreement. Regeneron maintains exclusive rights to Eylea in the US, and Bayer has licensed the exclusive marketing rights outside the US, where the companies share equally the profits from sales of Eylea, except for Japan where Regeneron receives a percentage of net sales.

Need Deeper Analysis? Sign up for Market Scope's monthly newsletter to get in-depth coverage of the ophthalmic market, including quarterly procedure volumes based on survey data and meeting coverage from around the world.

Recent Ophthalmic News

Ivantis Gains US FDA Approval for Hydrus Microstent

US FDA Approves Sun Pharma’s CEQUA for Dry Eye

Regeneron Receives US FDA Approval for 12-Week Eylea Dosing

STAAR, Japan’s Shinjuku LASIK Clinic Sign Multiyear Agreement

Alcon Launches Finesse Sharkskin ILM Forceps

Imprimis’ Q2-2018 Revenues Increase 51 Percent to $10.4 Million

Bausch Health Revenues in Q2-2018 Drop 5 Percent

TearLab’s Q2-2018 Revenues Drop 8.5 Percent to $6.4 Million

DeepMind AI System Accurately Detects Eye Disease in OCT Scans at Moorfields

Study by MIT, Mass Eye and Ear Suggests Glaucoma is Autoimmune Disease

Study Indicates Insulin May Restore Vision in Glaucoma

CHOP Researchers Define Six ROP Indicators

Nicox Initiates Phase II Study of NCX 470 in Open-Angle Glaucoma, Ocular Hypertension

Eyenovia’s Microdose Latanoprost Delivers Drug with Precision, Lowers IOP in Proof-of-Concept Study

Rayner to Launch Sulcoflex Trifocal Toric IOL in September

CMS Allows Medicare Advantage Plans to Apply Step Therapy to Retinal Injections

Glaukos Reports Drug Collaboration with D. Western, Q2-2018 Net Sales Increase of 5 Percent

Allergan Will Co-develop Editas’ CRISPR Genome Editing Candidate for LCA10

Spark Reports Q2-2018 Net Sales of $4.3 Million for Luxturna

Aerie’s Rhopressa Posts $2.4 Million in Net Revenues in Q2-2018

Coming soon

2018 Ophthalmic Laser Report: A Global Market Analysis for 2017 to 2023 (Photocoagulation, Photodisruption, and SLT